Novo Nordisk reported DKK594.94B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Bausch Health Companies USD 24.79B 296M Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Novo Nordisk DKK 90.92B 468.3B Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026